Genzyme & Aventis v. Novartis Gene Therapies — Dismissed With Prejudice in 271 Days
Genzyme Corporation and Aventis Inc. brought a patent infringement action against Novartis Gene Therapies Inc. and Novartis Pharmaceuticals Corporation in the Delaware District Court, asserting US10429288B2 covering analytical ultracentrifugation (AUC) methods for characterising recombinant viral particles. The parties jointly stipulated to dismiss all claims with prejudice after just 271 days — a notably swift resolution for gene therapy IP litigation.
Swift joint dismissal in a gene therapy AUC characterisation patent dispute
Filed on 19 May 2023 before Judge Richard G. Andrews in the Delaware District Court, this infringement action was brought by Genzyme Corporation and co-plaintiff Aventis Inc. against Novartis Gene Therapies Inc. and its parent Novartis Pharmaceuticals Corporation. The asserted patent, US10429288B2, relates to the use of analytical ultracentrifugation (AUC) for characterising recombinant viral particles — a technically specialised method increasingly relevant to AAV-based gene therapy manufacturing and quality control.
The case concluded on 14 February 2024 when both sides filed a joint stipulation of dismissal under Federal Rule of Civil Procedure 41(a)(1)(A)(ii). All claims asserted by any party were dismissed with prejudice, all pending motions and applications were simultaneously withdrawn, and each party agreed to bear its own legal fees and costs. The with-prejudice designation is legally significant: it extinguishes the plaintiffs’ right to bring the same infringement claims against Novartis in any future proceeding.
At 271 days from filing to closure, the resolution is notably swift for a Delaware pharmaceutical patent case, which typically advances through extended claim construction and expert discovery phases before any settlement. The mutual cost-bearing arrangement and the complete withdrawal of all pending motions suggest the parties reached a broader commercial accommodation — potentially a licensing arrangement or cross-licence — though the public record is silent on any underlying terms. The waiver of all appeal rights by both sides further reinforces the finality of the resolution.
Filing to dismissal in 271 days
271 days — faster than most comparable pharmaceutical patent infringement cases in Delaware
Joint stipulated dismissal with prejudice — what the terms mean for both parties
FRCP 41(a)(1)(A)(ii) — bilateral consent dismissal
Rule 41(a)(1)(A)(ii) permits both parties to jointly stipulate to dismiss an action at any stage without a court order. Unlike a unilateral voluntary dismissal, this route requires defendant consent, which typically signals a negotiated outcome rather than a plaintiff unilaterally walking away. The court accepted the stipulation as filed, and the case closed on the date of filing.
Bilateral — court order not requiredWith prejudice: the infringement claims are extinguished
A dismissal with prejudice operates as a final adjudication on the merits. Genzyme and Aventis are permanently barred from reasserting the same infringement claims based on US10429288B2 against Novartis Gene Therapies and Novartis Pharmaceuticals in any future action. This is a materially stronger outcome for Novartis than a without-prejudice dismissal, which would leave Novartis exposed to re-litigation. Both parties also waived all appeal rights.
No re-filing permittedEach party bears its own fees — no prevailing party designated
The stipulation explicitly provides that each party will bear its own fees and costs. Under US patent litigation norms, this ‘own costs’ arrangement is standard in negotiated dismissals and avoids the risk of an exceptional case fee award under 35 U.S.C. § 285. Neither side is designated the prevailing party, which is consistent with a commercially negotiated resolution rather than a court-imposed outcome.
No § 285 fee exposureAll motions withdrawn simultaneously — clean exit
The stipulation includes an express withdrawal of all pending motions, applications, and filings. This is a deliberate mechanism to achieve a clean procedural exit: no outstanding claim construction rulings, no Markman record, and no expert reports remain on the docket to be mined in collateral proceedings. The completeness of this withdrawal suggests the parties were motivated to eliminate any residual IP record that could affect related disputes or licensing negotiations.
No residual procedural recordFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Genzyme Corporation | Company | Sanofi-affiliated biotech and pharma entities — holders of US10429288B2Search in Eureka ↗ |
| Defendant | Novartis Gene Therapies, Inc. | Company | Novartis Gene Therapies Inc. and Novartis Pharmaceuticals Corporation — gene therapy developersSearch in Eureka ↗ |
| Plaintiff counsel | Amanda K. Antons | Attorney | Counsel for Genzyme CorporationSearch in Eureka ↗ |
| Plaintiff counsel | Brian M. Goldberg | Attorney | Counsel for Genzyme CorporationSearch in Eureka ↗ |
| Plaintiff counsel | Daniel Roberts | Attorney | Counsel for Genzyme CorporationSearch in Eureka ↗ |
| Plaintiff counsel | David E. Wilks | Attorney | Counsel for Genzyme CorporationSearch in Eureka ↗ |
| Plaintiff counsel | Donald C. Vavala , III | Attorney | Counsel for Genzyme CorporationSearch in Eureka ↗ |
| Plaintiff counsel | Jonathan D.J. Loeb | Attorney | Counsel for Genzyme CorporationSearch in Eureka ↗ |
| Plaintiff counsel | Judah Bellin | Attorney | Counsel for Genzyme CorporationSearch in Eureka ↗ |
| Plaintiff counsel | Katherine A. Helm | Attorney | Counsel for Genzyme CorporationSearch in Eureka ↗ |
| Plaintiff counsel | Martin J. Black | Attorney | Counsel for Genzyme CorporationSearch in Eureka ↗ |
| Plaintiff counsel | Noah M. Leibowitz | Attorney | Counsel for Genzyme CorporationSearch in Eureka ↗ |
| Plaintiff counsel | Pejmon Pashai | Attorney | Counsel for Genzyme CorporationSearch in Eureka ↗ |
| Plaintiff counsel | Scott B. Czerwonka | Attorney | Counsel for Genzyme CorporationSearch in Eureka ↗ |
| Plaintiff counsel | Sharon K. Gagliardi | Attorney | Counsel for Genzyme CorporationSearch in Eureka ↗ |
| Plaintiff counsel | Shyam Shanker | Attorney | Counsel for Genzyme CorporationSearch in Eureka ↗ |
| Defendant counsel | Alexandra M. Joyce | Attorney | Counsel for Novartis Gene Therapies, Inc.Search in Eureka ↗ |
| Defendant counsel | Cora R. Holt | Attorney | Counsel for Novartis Gene Therapies, Inc.Search in Eureka ↗ |
| Defendant counsel | Daniel M. Silver | Attorney | Counsel for Novartis Gene Therapies, Inc.Search in Eureka ↗ |
| Defendant counsel | Jeffrey D. Smyth | Attorney | Counsel for Novartis Gene Therapies, Inc.Search in Eureka ↗ |
| Defendant counsel | John D. Livingstone | Attorney | Counsel for Novartis Gene Therapies, Inc.Search in Eureka ↗ |
| Defendant counsel | M. David Weingarten , Ph.D | Attorney | Counsel for Novartis Gene Therapies, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Richard G. Andrews | Chief Judge | Delaware District Court — Chief JudgeSearch in Eureka ↗ |
Stipulation of dismissal — official text
The stipulation invokes FRCP 41(a)(1)(A)(ii), confirming this was a bilateral, consent-based dismissal rather than a unilateral walk-away. The with-prejudice designation and express waiver of all appeal rights provide Novartis with maximum finality: no risk of re-litigation on these specific claims. The simultaneous withdrawal of all pending motions means no claim construction record was created, leaving the scope of US10429288B2 unaddressed by the court — an important gap for third parties assessing their own exposure to this patent.
US10429288B2 — Analytical ultracentrifugation for recombinant viral particle characterisation
US10429288B2 (application number US15/544498) covers methods of using analytical ultracentrifugation (AUC) to characterise recombinant viral particles — a technique applied to distinguish full, empty, and partially loaded capsids in AAV and other vector preparations. AUC has become a critical analytical tool in gene therapy manufacturing, with regulatory agencies increasingly expecting capsid content ratio data for lot release and comparability studies. The patent’s application date and grant trajectory place it squarely in the period when AAV-based gene therapies were transitioning from clinical research into commercial manufacturing scale-up.
For competitors and CDMOs operating in the AAV and recombinant viral vector space, US10429288B2 represents a method patent with broad potential applicability across manufacturing workflows — not limited to a single therapeutic product. Genzyme’s willingness to assert it against Novartis Gene Therapies, one of the world’s largest gene therapy developers, suggests the patent holder views its claims as commercially significant and enforceable. The absence of any court-issued claim construction order means the precise scope remains unlitigated and potentially broader than defendants might prefer.
Should you run an FTO analysis against US10429288B2?
Any company developing, manufacturing, or providing CDMO services for AAV vectors or other recombinant viral particle products should consider whether their use of analytical ultracentrifugation for capsid characterisation — including full/empty capsid ratio determination for lot release — falls within the claims of US10429288B2. The patent has now survived litigation without any narrowing claim construction, meaning its scope as granted remains intact. Regulatory pressure to use AUC-based methods further concentrates exposure risk.
PatSnap Eureka’s FTO Search Agent allows R&D and IP teams to map their characterisation workflows against the full claim set of US10429288B2 and related family members, surfacing potential overlap before it becomes a litigation event. Eureka’s claim monitoring tools can also alert teams to continuation filings or divisionals in the same family that may extend coverage to adjacent analytical methods — giving product and manufacturing teams the intelligence they need to make informed design and sourcing decisions.
Run a freedom-to-operate analysis on US10429288B2 to assess your product’s exposure
Run FTO in Eureka →Similar patent cases involving gene therapy analytical methods and AAV characterisation IP
PatSnap Eureka tracks related litigation across truck body equipment, vehicle accessories, and comparable infringement actions in the Georgia district system.
What this case signals for the gene therapy analytical methods IP landscape
A swift bilateral dismissal with prejudice in AAV characterisation IP suggests active commercial negotiation — and raises portfolio monitoring questions for the sector.
AUC-based viral particle characterisation is actively being asserted as IP
The filing of this case signals that analytical methods used in gene therapy manufacturing — not just the therapeutic constructs themselves — are subject to active patent enforcement. Companies developing AAV or other recombinant viral vector products should audit whether their characterisation workflows touch claims in US10429288B2 or related family members.
Bilateral with-prejudice dismissal within 9 months is consistent with early licensing
The speed, mutual cost-bearing, and complete motion withdrawal are hallmarks of a negotiated commercial outcome — potentially a licence, cross-licence, or technology access agreement. Competitors in the gene therapy space should consider whether a similar resolution path is available to them, rather than assuming litigation will run its full course.
Genzyme v Novartis — key questions answered
The case was dismissed with prejudice by joint stipulation under FRCP 41(a)(1)(A)(ii) on 14 February 2024, approximately 271 days after filing. All claims were extinguished, all pending motions withdrawn, and each party agreed to bear its own fees and costs. Both parties waived all appeal rights.
Genzyme Corporation and Aventis Inc. asserted US10429288B2 (application number US15/544498), which relates to analytical ultracentrifugation (AUC) methods for the characterisation of recombinant viral particles — a technique used in gene therapy manufacturing to assess capsid content.
A dismissal with prejudice operates as a final adjudication on the merits. Genzyme Corporation and Aventis Inc. are permanently barred from reasserting the same infringement claims based on US10429288B2 against Novartis Gene Therapies Inc. or Novartis Pharmaceuticals Corporation in any future action. All appeal rights were also waived.
The 271-day resolution is notably swift for a Delaware pharmaceutical patent case. The bilateral nature of the dismissal, the mutual cost-bearing arrangement, the simultaneous withdrawal of all pending motions, and the with-prejudice designation are all consistent with a negotiated commercial outcome — possibly a licensing agreement — though no terms are disclosed in the public record.
US10429288B2 covers AUC-based characterisation methods for recombinant viral particles, a process increasingly required in AAV manufacturing for regulatory lot-release and comparability studies. The patent has not been subject to any claim construction ruling, so its scope remains unlitigated. Companies and CDMOs using AUC in viral vector workflows should assess their exposure to this patent and its family members.
PatSnap Eureka searches patents and litigation data to answer instantly.